Eli Lilly and Company (LLY)
- Motley Fool
Will Eli Lilly Be a Trillion-Dollar Stock by 2030?
Achieving a trillion-dollar market cap is a significant milestone for any business. It's an exclusive club that includes top companies such as Apple and Microsoft. Companies worth $1 trillion are among the best of the best, and owning a stock that could be worth that much in the future could mean a huge return for investors.
- Motley Fool
1 Stock Down 9% in 2023 to Buy and Hold Forever
Despite its poorer fortunes so far this year -- the stock is down 9% -- there are excellent reasons to load up on Eli Lilly's shares with expectations of even better days ahead. Eli Lilly recently made news when it announced it was slashing the price of its insulin products by 70% and capped out-of-pocket costs at $35 per month. One of the reasons the move generated so much attention is that Eli Lilly is one of just three companies that control nearly the entire insulin market worldwide.
- Reuters
Roche teams up with Lilly to validate Alzheimer's blood test
Roche and Eli Lilly and Co are joining forces to develop a blood test for Alzheimer's disease, and plan to kick off a two-year clinical trial involving hundreds of volunteers with the aim of winning U.S. regulatory approval. The effort, unveiled in a statement on Wednesday, comes as Lilly as well as Eisai and Biogen are gearing up to sell drugs aimed at slowing the advance of the mind-robbing illness, but their use will require a diagnosis at earlier disease stages than is the norm today. Roche Holding AG would recruit several hundred volunteers with early signs of dementia over the next 18 to 24 months with trial data potentially ready for a U.S. regulatory filing in 2025, Bruce Jordan, leader of Personalized Healthcare Solutions at Roche Diagnostics, told Reuters.
